Christopher Michael Lyons, a director at Sintx Technologies, Inc. (NASDAQ:SINT), recently increased his stake in the company through two open-market purchases of common stock. A Form 4 filing with the Securities and Exchange Commission shows Lyons bought a total of 8,292 shares, paying $24,092 across the two transactions.
The filings detail that the first transaction took place on February 25, 2026, when Lyons purchased 758 shares at $2.96 per share. The second transaction occurred on March 2, 2026, when he acquired 7,534 shares at $2.90 per share. After these purchases, Lyons directly owns 8,292 shares of Sintx Technologies.
The reported trades were executed at prices that exceeded the company's most recent market quote of $2.75. The stock is down 29% year-to-date and has declined 15% over the past 12 months. InvestingPro analysis cited in the filing places a Fair Value for the stock at $2.97, indicating that the current trading price is below that estimate. The InvestingPro note included in the filing also states that Sintx holds more cash than debt on its balance sheet, but it is consuming cash rapidly - a behavior highlighted as a cautionary point among additional insights provided to subscribers.
The Form 4 indicates the transactions were signed by Kevin Ontiveros, acting by power of attorney on behalf of Lyons.
Corporate leadership update
In a separate disclosure, Sintx Technologies announced the appointment of Ryan Elmore as president, with the appointment effective March 16, 2026. The company said Elmore joins Sintx from Invibio, a division of Victrex plc, where he served as Core Business Director. The filing notes Elmore brings more than 15 years of experience in advanced biomaterials and medical device commercialization to his new role.
Sintx has not released additional details regarding any strategic initiatives, operational changes, or specific priorities that Elmore will pursue as president. Investors and other stakeholders will likely watch for future communications from the company to understand how this leadership change may influence its direction.
What is known and what remains limited
- All insider purchase amounts, dates, and per-share prices are reported on the SEC Form 4 as described above.
- The market price cited and the InvestingPro Fair Value estimate are presented in the filing; the latter suggests the stock may be trading below a referenced fair value.
- The company's balance sheet position is summarized as having more cash than debt, but the filing also signals rapid cash consumption without providing further detail on the timeline or drivers of that burn.
The information in the filings provides specific transactional and leadership details, while leaving strategic implications and future operational plans unreported by the company at this time.